tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jul 25;13(1):11327.
doi: 10.1038/s41598-023-36990-9. A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Thomas Starkey[SUP] #[/SUP][SUP] 1 [/SUP], Maria C Ionescu[SUP] #[/SUP][SUP] 2 [/SUP], Michael Tilby[SUP] #[/SUP][SUP] 3 [/SUP], Martin Little[SUP] #[/SUP][SUP] 4 [/SUP], Emma Burke[SUP] #[/SUP][SUP] 4 [/SUP], Matthew W Fittall[SUP] #[/SUP][SUP] 5 [/SUP], Sam Khan[SUP] #[/SUP][SUP] 6 [/SUP], Justin K H Liu[SUP] #[/SUP][SUP] 7 [/SUP], James R Platt[SUP] #[/SUP][SUP] 8 [/SUP], Rosie Mew[SUP] #[/SUP][SUP] 9 [/SUP], Arvind R Tripathy[SUP] #[/SUP][SUP] 10 [/SUP], Isabella Watts[SUP] #[/SUP][SUP] 11 [/SUP], Sophie Therese Williams[SUP] #[/SUP][SUP] 12 [/SUP], Nathan Appanna[SUP] 13 [/SUP], Youssra Al-Hajji[SUP] 14 [/SUP], Matthew Barnard[SUP] 2 [/SUP], Liza Benny[SUP] 2 [/SUP], Alexander Burnett[SUP] 15 [/SUP], Jola Bytyci[SUP] 16 [/SUP], Emma L Cattell[SUP] 17 [/SUP], Vinton Cheng[SUP] 7 [/SUP], James J Clark[SUP] 18 [/SUP], Leonie Eastlake[SUP] 19 [/SUP], Kate Gerrand[SUP] 2 [/SUP], Qamar Ghafoor[SUP] 3 [/SUP], Simon Grumett[SUP] 3 [/SUP], Catherine Harper-Wynne[SUP] 20 [/SUP], Rachel Kahn[SUP] 21 [/SUP], Alvin J X Lee[SUP] 22 [/SUP], Oliver Lomas[SUP] 4 [/SUP], Anna Lydon[SUP] 9 [/SUP], Hayley Mckenzie[SUP] 23 [/SUP]; NCRI Consumer Forum; Hari Panneerselvam[SUP] 24 [/SUP], Jennifer S Pascoe[SUP] 3 [/SUP], Grisma Patel[SUP] 22 [/SUP], Vijay Patel[SUP] 25 [/SUP], Vanessa A Potter[SUP] 26 [/SUP], Amelia Randle[SUP] 27 [/SUP], Anne S Rigg[SUP] 28 [/SUP], Tim M Robinson[SUP] 29 [/SUP], Rebecca Roylance[SUP] 30 [/SUP], Tom W Roques[SUP] 31 [/SUP], Stefan Rozmanowski[SUP] 2 [/SUP], René L Roux[SUP] 4 [/SUP], Ketan Shah[SUP] 4 [/SUP], Remarez Sheehan[SUP] 32 [/SUP], Martin Sintler[SUP] 33 [/SUP], Sanskriti Swarup[SUP] 16 [/SUP], Harriet Taylor[SUP] 13 [/SUP], Tania Tillett[SUP] 34 [/SUP], Mark Tuthill[SUP] 4 [/SUP], Sarah Williams[SUP] 3 [/SUP], Yuxin Ying[SUP] 16 [/SUP], Andrew Beggs[SUP] 1 [/SUP], Tim Iveson[SUP] 23 [/SUP], Siow Ming Lee[SUP] 30 [/SUP], Gary Middleton[SUP] 35 [/SUP], Mark Middleton[SUP] 16 [/SUP], Andrew Protheroe[SUP] 36 [/SUP], Tom Fowler[SUP] 2 37 [/SUP], Peter Johnson[SUP] 38 [/SUP], Lennard Y W Lee[SUP] 39 40 [/SUP]
Collaborators, Affiliations
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
. 2023 Jul 25;13(1):11327.
doi: 10.1038/s41598-023-36990-9. A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Thomas Starkey[SUP] #[/SUP][SUP] 1 [/SUP], Maria C Ionescu[SUP] #[/SUP][SUP] 2 [/SUP], Michael Tilby[SUP] #[/SUP][SUP] 3 [/SUP], Martin Little[SUP] #[/SUP][SUP] 4 [/SUP], Emma Burke[SUP] #[/SUP][SUP] 4 [/SUP], Matthew W Fittall[SUP] #[/SUP][SUP] 5 [/SUP], Sam Khan[SUP] #[/SUP][SUP] 6 [/SUP], Justin K H Liu[SUP] #[/SUP][SUP] 7 [/SUP], James R Platt[SUP] #[/SUP][SUP] 8 [/SUP], Rosie Mew[SUP] #[/SUP][SUP] 9 [/SUP], Arvind R Tripathy[SUP] #[/SUP][SUP] 10 [/SUP], Isabella Watts[SUP] #[/SUP][SUP] 11 [/SUP], Sophie Therese Williams[SUP] #[/SUP][SUP] 12 [/SUP], Nathan Appanna[SUP] 13 [/SUP], Youssra Al-Hajji[SUP] 14 [/SUP], Matthew Barnard[SUP] 2 [/SUP], Liza Benny[SUP] 2 [/SUP], Alexander Burnett[SUP] 15 [/SUP], Jola Bytyci[SUP] 16 [/SUP], Emma L Cattell[SUP] 17 [/SUP], Vinton Cheng[SUP] 7 [/SUP], James J Clark[SUP] 18 [/SUP], Leonie Eastlake[SUP] 19 [/SUP], Kate Gerrand[SUP] 2 [/SUP], Qamar Ghafoor[SUP] 3 [/SUP], Simon Grumett[SUP] 3 [/SUP], Catherine Harper-Wynne[SUP] 20 [/SUP], Rachel Kahn[SUP] 21 [/SUP], Alvin J X Lee[SUP] 22 [/SUP], Oliver Lomas[SUP] 4 [/SUP], Anna Lydon[SUP] 9 [/SUP], Hayley Mckenzie[SUP] 23 [/SUP]; NCRI Consumer Forum; Hari Panneerselvam[SUP] 24 [/SUP], Jennifer S Pascoe[SUP] 3 [/SUP], Grisma Patel[SUP] 22 [/SUP], Vijay Patel[SUP] 25 [/SUP], Vanessa A Potter[SUP] 26 [/SUP], Amelia Randle[SUP] 27 [/SUP], Anne S Rigg[SUP] 28 [/SUP], Tim M Robinson[SUP] 29 [/SUP], Rebecca Roylance[SUP] 30 [/SUP], Tom W Roques[SUP] 31 [/SUP], Stefan Rozmanowski[SUP] 2 [/SUP], René L Roux[SUP] 4 [/SUP], Ketan Shah[SUP] 4 [/SUP], Remarez Sheehan[SUP] 32 [/SUP], Martin Sintler[SUP] 33 [/SUP], Sanskriti Swarup[SUP] 16 [/SUP], Harriet Taylor[SUP] 13 [/SUP], Tania Tillett[SUP] 34 [/SUP], Mark Tuthill[SUP] 4 [/SUP], Sarah Williams[SUP] 3 [/SUP], Yuxin Ying[SUP] 16 [/SUP], Andrew Beggs[SUP] 1 [/SUP], Tim Iveson[SUP] 23 [/SUP], Siow Ming Lee[SUP] 30 [/SUP], Gary Middleton[SUP] 35 [/SUP], Mark Middleton[SUP] 16 [/SUP], Andrew Protheroe[SUP] 36 [/SUP], Tom Fowler[SUP] 2 37 [/SUP], Peter Johnson[SUP] 38 [/SUP], Lennard Y W Lee[SUP] 39 40 [/SUP]
Collaborators, Affiliations
- PMID: 37491478
- DOI: 10.1038/s41598-023-36990-9
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.